Analysis of the Human CD10/Neutral Endopeptidase 24.11 Promoter Region: Two Separate Regulatory Elements
The cell surface zinc metalloproteinase CD10/neutral endopeptidase 24.11 (NEP) is expressed on normal and malignant lymphoid progenitors, granulocytes, and a variety of epithelial cells. To further define the tissue-specific and develop-mentally related expression of CD10/NEP, we have characterized...
Saved in:
Published in | Blood Vol. 85; no. 11; pp. 3199 - 3207 |
---|---|
Main Authors | , |
Format | Journal Article |
Language | English |
Published |
Washington, DC
Elsevier Inc
01.06.1995
The Americain Society of Hematology |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The cell surface zinc metalloproteinase CD10/neutral endopeptidase 24.11 (NEP) is expressed on normal and malignant lymphoid progenitors, granulocytes, and a variety of epithelial cells. To further define the tissue-specific and develop-mentally related expression of CD10/NEP, we have characterized two separate regulatory regions that control the transcription of 5‘ alternatively spliced CD10/NEP transcripts. These type 1 and 2 CD10/NEP regulatory regions are both characterized by the presence of multiple transcription initiation sites and the absence of classic TATA boxes and consensus initiator elements. The purine-rich type 1 regulatory region, which includes 5‘ UTR exon 1 sequence, is characterized by multiple putative PU.1 binding sites and consensus efs-binding motifs. In marked contrast, the GC-rich type 2 regulatory region contains multiple putative Sp1 binding sites, a potential consensus retinoblastoma control element (RCE), and an inverted CCAAT box. In the majority of tissues examined to date, type 2 CD10/NEP transcripts were more abundant; the abundance of type 1 transcripts was more variable, with the highest type 1 levels in fetal thymus and certain lymphoblastic leukemia cell lines. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 0006-4971 1528-0020 |
DOI: | 10.1182/blood.V85.11.3199.bloodjournal85113199 |